ArticlePloS one2021
Ayurveda botanicals in COVID-19 management: An in silico multi-target approach.
Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 95 citations in OpenAlex.
- Safe prolonged prophylactic use and tolerability of Ashwagandha following COVISHIELD™ vaccination over 24 weeks: a multicentre randomized double-blind placebo-controlled trial.Frontiers in medicine · 2026Trial
- Shatavari supplementation in postmenopausal women alters the skeletal muscle proteome and pathways involved in training adaptation.European journal of nutrition · 2024Trial
- [Cephaeline attenuates malignant biological behaviors of colorectal cancer by regulating the Ras signaling pathway].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026Article
- In-silico screening, molecular dynamics simulation and ADME evaluation ofIn silico pharmacology · 2025Article
- Deciphering the multi-scale mechanism of herbal phytoconstituents in targeting breast cancer: a computational pharmacological perspective.Scientific reports · 2024Article
- Phytochemical analysis ofWorld journal of experimental medicine · 2024Review
- Network pharmacology, molecular docking, and in vitro study on Aspilia pluriseta against prostate cancer.BMC complementary medicine and therapies · 2024Article
- Precision nutrition to reset virus-induced human metabolic reprogramming and dysregulation (HMRD) in long-COVID.NPJ science of food · 2024Review
- Genome sequencing and functional analysis of a multipurpose medicinal herb Tinospora cordifolia (Giloy).Scientific reports · 2024Article
- Mitochondrial resilience and antioxidant defence against HIV-1: unveiling the power ofFrontiers in microbiology · 2024Article
- Steroidal lactones fromIn silico pharmacology · 2024Article
- Withania somnifera extracts induced attenuation of HIV-1: a mechanistic approach to restrict viral infection.Virology journal · 2023Article
- Exploration of multifaceted molecular mechanism of angiotensin-converting enzyme 2 (ACE2) in pathogenesis of various diseases.Heliyon · 2023Review
- Ayurveda and in silico Approach: A Challenging Proficient Confluence for Better Development of Effective Traditional Medicine Spotlighting Network Pharmacology.Chinese journal of integrative medicine · 2023Review
- Inhibition of SARS-CoV2 viral infection with natural antiviral plants constituents: An in-silico approach.Journal of King Saud University. Science · 2023Article
- Phytomedicines explored underSouth African journal of botany : official journal of the South African Association of Botanists = Suid-Afrikaanse tydskrif vir plantkunde : amptelike tydskrif van die Suid-Afrikaanse Genootskap van Plantkundiges · 2022Review
- Frequently Used Allopathic and Traditional Medicine for COVID-19 Treatment and Feasibility of Their Integration.Chinese journal of integrative medicine · 2022Review
- Ayurvedic formulations: Potential COVID-19 therapeutics?Phytomedicine plus : international journal of phytotherapy and phytopharmacology · 2022Review
- Article
- Unveiling the nature's fruit basket to computationally identify Citrus sinensis csi-mir169-3p as a probable plant miRNA against Reference and Omicron SARS-CoV-2 genome.Computers in biology and medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Coronavirus disease (COVID-19) caused by the virus SARS-CoV-2 has become a global pandemic in a very short time span. Currently, there is no specific treatment or vaccine to counter this highly contagious disease. There is an urgent need to find a specific cure for the disease and global efforts are directed at developing SARS-CoV-2 specific antivirals and immunomodulators. Ayurvedic Rasayana therapy has been traditionally used in India for its immunomodulatory and adaptogenic effects, and more recently has been included as therapeutic adjuvant for several maladies. Amongst several others, Withania somnifera (Ashwagandha), Tinospora cordifolia (Guduchi) and Asparagus racemosus (Shatavari) play an important role in Rasayana therapy. The objective of this study was to explore the immunomodulatory and anti SARS-CoV2 potential of phytoconstituents from Ashwagandha, Guduchi and Shatavari using network pharmacology and docking. The plant extracts were prepared as per ayurvedic procedures and a total of 31 phytoconstituents were identified using UHPLC-PDA and mass spectrometry studies. To assess the immunomodulatory potential of these phytoconstituents an in-silico network pharmacology model was constructed. The model predicts that the phytoconstituents possess the potential to modulate several targets in immune pathways potentially providing a protective role. To explore if these phytoconstituents also possess antiviral activity, docking was performed with the Spike protein, Main Protease and RNA dependent RNA polymerase of the virus. Interestingly, several phytoconstituents are predicted to possess good affinity for the three targets, suggesting their application for the termination of viral life cycle. Further, predictive tools indicate that there would not be adverse herb-drug pharmacokinetic-pharmacodynamic interactions with concomitantly administered drug therapy. We thus make a compelling case to evaluate the potential of these Rasayana botanicals as therapeutic adjuvants in the management of COVID-19 following rigorous experimental validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.